Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Acquired by Opal Wealth Advisors LLC

Opal Wealth Advisors LLC lifted its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 16.9% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 1,386 shares of the medical research company’s stock after buying an additional 200 shares during the quarter. Opal Wealth Advisors LLC’s holdings in Thermo Fisher Scientific were worth $690,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Norges Bank acquired a new stake in Thermo Fisher Scientific in the 4th quarter valued at about $3,149,754,000. GAMMA Investing LLC grew its stake in Thermo Fisher Scientific by 60,610.9% during the 1st quarter. GAMMA Investing LLC now owns 2,419,331 shares of the medical research company’s stock worth $1,203,859,000 after buying an additional 2,415,346 shares during the last quarter. T. Rowe Price Investment Management Inc. grew its stake in Thermo Fisher Scientific by 86.9% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,083,900 shares of the medical research company’s stock worth $1,604,338,000 after buying an additional 1,433,444 shares during the last quarter. Kovitz Investment Group Partners LLC grew its stake in Thermo Fisher Scientific by 1,905.4% during the 4th quarter. Kovitz Investment Group Partners LLC now owns 903,232 shares of the medical research company’s stock worth $469,889,000 after buying an additional 858,193 shares during the last quarter. Finally, Proficio Capital Partners LLC grew its stake in Thermo Fisher Scientific by 68,617.0% during the 4th quarter. Proficio Capital Partners LLC now owns 762,759 shares of the medical research company’s stock worth $396,810,000 after buying an additional 761,649 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling

In related news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction on Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the transaction, the executive vice president now directly owns 23,167 shares of the company’s stock, valued at approximately $9,960,188.31. The trade was a 1.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. 0.33% of the stock is currently owned by insiders.

Analysts Set New Price Targets

TMO has been the topic of a number of research reports. Scotiabank dropped their price target on Thermo Fisher Scientific from $650.00 to $605.00 and set a “sector perform” rating on the stock in a research note on Friday, April 25th. Citigroup dropped their price target on Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 4th. Wall Street Zen upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Wednesday, May 21st. Robert W. Baird lowered their target price on Thermo Fisher Scientific from $603.00 to $573.00 and set an “outperform” rating on the stock in a research note on Thursday, April 24th. Finally, Stifel Nicolaus lowered their target price on Thermo Fisher Scientific from $665.00 to $620.00 and set a “buy” rating on the stock in a research note on Thursday, April 24th. Four equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $605.30.

Thermo Fisher Scientific Stock Down 3.2%

TMO opened at $402.12 on Friday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. The business has a 50 day simple moving average of $416.80 and a 200-day simple moving average of $492.39. The stock has a market capitalization of $151.80 billion, a P/E ratio of 24.33, a P/E/G ratio of 2.99 and a beta of 0.78. Thermo Fisher Scientific Inc. has a 12 month low of $390.50 and a 12 month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $5.10 by $0.05. The business had revenue of $10.36 billion during the quarter, compared to analysts’ expectations of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The company’s quarterly revenue was up .2% compared to the same quarter last year. During the same period last year, the firm earned $5.11 EPS. On average, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Friday, June 13th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, June 13th. This represents a $1.72 annualized dividend and a yield of 0.43%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.09%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.